AEON Biopharma
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 10
- Market Cap
- $36.1M
- Website
- http://www.aeonbiopharma.com
- Introduction
AEON Biopharma, Inc. is a biopharmaceutical company. It engages in the business of developing proprietary botulinum toxin complex, ABP-450 injection, for debilitating medical conditions. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Irvine, CA.
Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention
- Conditions
- Migraine
- Interventions
- Drug: ABP-450
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- AEON Biopharma, Inc.
- Target Recruit Count
- 666
- Registration Number
- NCT05016661
- Locations
- 🇺🇸
Quest Research Institute - Hunt - PPDS, Farmington Hills, Michigan, United States
🇺🇸NeuroTrials Research Inc. - Clinedge - PPDS, Atlanta, Georgia, United States
🇺🇸Kansas Institute of Research, LLC, Overland Park, Kansas, United States
Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia
- Conditions
- Cervical Dystonia
- Interventions
- Drug: ABP-450
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- AEON Biopharma, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT04871451
- Locations
- 🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States
🇺🇸New England Institute for Neurology and Headache, Stamford, Connecticut, United States
🇺🇸Neuro Pain Medical Center, Fresno, California, United States
A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia
- Conditions
- Cervical Dystonia
- Interventions
- Drug: ABP-450Drug: Placebo
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- AEON Biopharma, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT04849988
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Neuro Pain Medical Center, Fresno, California, United States
🇺🇸Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States
Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults
- Conditions
- Migraine
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- AEON Biopharma, Inc.
- Target Recruit Count
- 797
- Registration Number
- NCT04845178